Last reviewed · How we verify
ZSP1273
ZSP1273 is an influenza virus RNA-dependent RNA polymerase inhibitor that blocks viral replication.
ZSP1273 is an influenza virus RNA-dependent RNA polymerase inhibitor that blocks viral replication. Used for Treatment of acute uncomplicated influenza A and B in adults and adolescents aged 12 years and older.
At a glance
| Generic name | ZSP1273 |
|---|---|
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Drug class | RNA-dependent RNA polymerase inhibitor |
| Target | Influenza virus RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the RNA-dependent RNA polymerase, ZSP1273 prevents the influenza virus from replicating its genetic material, thereby reducing viral load and mitigating the severity of the infection.
Approved indications
- Treatment of acute uncomplicated influenza A and B in adults and adolescents aged 12 years and older
Common side effects
- Nausea
- Headache
Key clinical trials
- Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A (PHASE3)
- Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A (PHASE3)
- Pharmacokinetics，Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A (PHASE2)
- Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China (PHASE1)
- Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease (PHASE1)
- Bioavailability Study in Healthy Participants, 200mg Tablets ZSP1273 Versus 200mg Granules ZSP1273 (PHASE1)
- Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid (PHASE1)
- A Drug Interaction Study Assess the Effects of ZSP1273 Tablets on the Pharmacokinetics of Warfarin and Midazolam (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZSP1273 CI brief — competitive landscape report
- ZSP1273 updates RSS · CI watch RSS
- Guangdong Raynovent Biotech Co., Ltd portfolio CI